Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China; Key Laboratory of Intelligent Drug Design and New Drug Discovery of Liaoning Province, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China; School of Medical Devices, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China.
Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China; Key Laboratory of Intelligent Drug Design and New Drug Discovery of Liaoning Province, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China; School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China.
Comput Biol Chem. 2023 Jun;104:107836. doi: 10.1016/j.compbiolchem.2023.107836. Epub 2023 Feb 22.
Research onβ-AR, the new member of the adrenoceptor family, is in its infancy and few β-AR agonists have been approved for marketing to date. Meanwhile, β-AR exhibited obvious species differences in pharmacological properties, such as between human and animals, however, the 3D structure of human β-AR has not been published, which makes it difficult to understand the interaction between human β-AR and its agonists. Herein, binding patterns of β-AR agonists are explored starting from the Alphafold predicted structural model, and the obtained model was optimized by using molecular dynamics simulations. Moreover, the human β-AR and its agonists were subjected to molecular docking, dynamics simulations, binding free energy calculations and pharmacophore modeling to elucidate the characteristics of human β-AR activity pockets and agonist conformational relationships, including a hydrophobic group, a positively charged group as well as two hydrogen-bonded donors, which provide comprehensive insights into the interactions between human β-AR and its agonists.
β-AR 是肾上腺素能受体家族的新成员,目前对其研究尚处于起步阶段,仅有少数 β-AR 激动剂获准上市。同时,β-AR 在药理学特性上表现出明显的种属差异,例如在人与动物之间,但人类β-AR 的 3D 结构尚未公布,这使得难以理解人类β-AR 与其激动剂之间的相互作用。本文从 Alphafold 预测的结构模型出发,探索了β-AR 激动剂的结合模式,并通过分子动力学模拟对获得的模型进行了优化。此外,对人β-AR 及其激动剂进行了分子对接、动力学模拟、结合自由能计算和药效团建模,以阐明人β-AR 活性口袋和激动剂构象关系的特征,包括一个疏水区、一个正电荷基团以及两个氢键供体,这为深入了解人β-AR 与其激动剂之间的相互作用提供了全面的认识。